Human Behavior

The Surprisingly Simple Way Researchers Say a Second COVID-19 Wave Could Be Avoided – SciTechDaily

A Second COVID-19 Wave Could Be Avoided if Social Distancing and the Use of Face Masks Are Maintained

A model developed by ISGlobal shows that deconfinement must be gradual and that individual behavior is a key factor.

Individual behavior has a significant effect on preventing a large second wave of COVID-19 infections. In fact, maintaining social distancing and other interventions such as the use of face masks and hand hygiene could remove the need for future lockdowns, according to a modeling study performed by the Barcelona Institute for Global Health (ISGlobal), an institution supported by the la Caixa Foundation. The findings, published in Nature Human Behaviour, also show that, in countries that have not yet reached the peak of active cases, lockdowns must remain in place for at least 60 days and deconfinement must be gradual in order to decrease the risk of second waves.

Several countries that initially imposed strict lockdown measures to limit the spread of SARS-CoV-2 are in the process of lifting them. However, how and when to ease the restrictions is a difficult decision a delicate balance between the need to reactivate the economy and the risk of a second wave of infections that could overwhelm healthcare systems. The problem is that assessing this risk is difficult, given the lack of reliable information on the actual number of people infected or the extent of immunity developed among the population, explains Xavier Rod, head of ISGlobals Climate and Health program. In this study, Rods team present projections based on a model that divides the population into seven groups: susceptible, quarantined, exposed, infectious not detected, reported infectious and confined, recovered and death. It also allows to simulate both the degree of population confinement and the different post-confinement strategies.

Our model is different because it considers the return of confined people to the susceptible population to estimate the effect of deconfinement, and it includes peoples behaviors and risk perception as modulating factors, explains Xavier Rod. This model can be particularly useful for countries where the peak of cases has not yet been reached, such as those in the Southern hemisphere. It would allow to evaluate control policies and minimize the number of cases and fatalities caused by the virus explains co-author and ISGlobal researcher Leonardo Lpez.

The use of face masks, hand hygiene and shelter in place mandates have already demonstrated benefits. The aim of this study was to quantitatively evaluate their relevance as containment strategies. The results clearly show that the length of the first confinement will affect the timing and magnitude of subsequent waves, and that gradual deconfinement strategies always result in a lower number of infections and deaths, when compared to a very fast deconfinement process.

In Spain, where the deconfinement was fast for half of the population and gradual for the rest, individual behavior will be key for reducing or avoiding a second wave. If we manage to reduce transmission rate by 30% through the use of face masks, hand hygiene, and social distancing, we can considerably reduce the magnitude of the next wave. Reducing transmission rate by 50% could avoid it completely, says Rod.

The results show that, even in countries that do not have the resources to test and trace all cases and contacts, social empowerment through the use of masks, hand hygiene, and social distancing, is key to stopping viral transmission.

Simulations also show that loss of immunity to the virus will have significant effects on the spacing between epidemic waves if immunity has a long duration (one year instead of a few months), then the time between the epidemic waves will double.

The model considered total lockdowns and used data available until May 25, but did not take into account a possible effect of temperatures on viral transmission.

Reference: The end of social confinement and COVID-19 re-emergence risk by Leonardo Lpez and Xavier Rod, 22 June 2020, Nature Human Behaviour.DOI: 10.1038/s41562-020-0908-8

Read the original:
The Surprisingly Simple Way Researchers Say a Second COVID-19 Wave Could Be Avoided - SciTechDaily

Physiology

USF researchers working to find early warnings for severe COVID-19 illness – ABC Action News

TAMPA, Fla. -- Researchers at the University of South Florida are working to identify the physiological response to COVID-19, in hopes of developing an early warning system for patients who may be at risk for severe illness.

Researchers explained their goal is to understand which physiological patterns may give an indicator of a more serious infection.

Well be able to define how long people have these different abnormalities, their vital signs, their activity level, their heart so that we will know more about how to triage patients, characterize patients, tell them what to expect coming down the line on different days of their illness, said Dr. Asa Oxner, an associate professor at USF and operations director of the TGH-USF Health COVID Clinic.

What we intend to do is monitor a large enough sample population of people who have contracted the COVID virus but do not have otherwise some other secondary condition that would indicate they are at high risk and see if we can identify relative to their those outcomes which of the variables might give us an early indication that for a particular physiology youre going sideways, said Dr. Matthew Mallarkey, director of the USF Muma College of Businesss Doctor of Business Administration Program.

They are monitoring up to 150 COVID-19 patients with no underlying risk factors for up to a month after their diagnosis. The patients will wear a device from Shimmer Research Inc., partnering with USF on the study, to measure things like heart rate, oxygen, heart rhythm and activate levels.

Unfortunately, COVID-19 is likely to be with us for a while. By monitoring patients, we can direct healthcare resources to those who really need it and intervene in severe cases before they turn critical. This can be done remotely without bringing infectious patients to hospitals or doctors offices where they can infect other people. We are excited to work with the excellent team at USF, who bring world-class medical and AI expertise to this project, the company stated.

Researchers said theyll look at the data to see if there are the same signs in patients.

We can look back on the ones who got worse, what was the first sign that theyre about to get worse and do they all have the same sign? If they did, thats very very helpful for the people out in the community. We could have patients self-monitor that or we could have primary care doctors self-monitor that so that we would know whos gonna get sick and we know early as possible so we can start changing things for them, said Oxner.

Were hearing about sports teams, for example, where whole teams -- one or two members of the team -- contract the virus and maybe whole teams are at risk of contracting the virus. We would imagine that theres a better world where those otherwise healthy young adults are given a wearable device that could continuously monitor and compare their physiologies to these identified archetypes that these archetypes that are gonna go sideways and they dont go sideways for the same reason, said Mallarkey.

The project is funded through the USF COVID-19 Rapid Response Grant.

Originally posted here:
USF researchers working to find early warnings for severe COVID-19 illness - ABC Action News

Physiology

Affluent Medical kicks off first-in-human trial of Epygon valve – BioWorld Online

French startup Affluent Medical SA has launched a European pilot study in humans of its native-like transcatheter mitral valve technology. The Epygon valve is designed to restore the normal blood flow vortex in the left side of the heart and treat left ventricle disease, particularly in so-called functional patients.

Coinciding with the launch of the pilot, the company announced 10.3 million (US$11.6 million) in new financing and the addition of three new members on its board of directors.

According to the Aix-en-Provence company, the Epygon valves asymmetric, D-shaped and one-leaflet design allows it to restore the natural vortex, a rotational blood flow that is thought to be more efficient that a straight, steady flow. To our knowledge, no other mitral valve in development is a one-leaflet allowing the restore the physiological vortex, CEO Michel Finance told BioWorld.

The unique design is expected to result in high procedural success, restore left ventricular blood flow and avoid thrombus formation and left ventricular outflow tract (LVOT) obstruction, while also reducing left ventricular effort.

Finance called the pilot study a major milestone for the company.

Epygon is a world premiere and a potential best-in-class valve in a market where physiology has been overlooked for decades, he said. This pilot study aims to confirm the improved clinical outcomes already demonstrated in preclinical testing. It should open up a new era both for surgeons and patients, with physiology as a key factor in cardiac surgery.

CE mark pivotal study targeted for 2022

Affluent Medical estimates that as many as 4 million people in the U.S., Europe and Asia suffer from mitral valve regurgitation, due to the lack of optimal therapies. The global market is expected to reach $3.5 billion to $5 billion by the end of 2022, growing at an annual rate of 35%.

The prospective, nonrandomized, single-arm, multicenter MINERVA (Mitral valve INsufficiency with the Epygon TRanscatheter mitral VAlve system) study will enroll up to 20 patients in three centers in Austria, Italy and Spain. Affluent Medical plans to complete enrollment by the first quarter of 2021 and report the results after one year of follow-up.

We are anticipating our first human implant in the next weeks, Finance said.

If the pilot study is successful, the company plans to launch a pivotal trial to support CE marking of the Epygon valve in early 2022.

Finance said the company will be pursuing a similar approach for U.S. FDA approval, starting most probably in the next six to 12 months.

Capital injection

The 10.3 million private placement financing was led by Truffle Capital via the Truffle Biomedtech FCPI Fund and Truffle Innov FRR France. Other participants included Head Leader Ltd., Affluent Medicals partner for two ventures in Shanghai, Ginko Invest, Fate and Simone Merkle. The company has earmarked the funds to advance its cardiology clinical programs, particularly the MINERVA study, completion of its OPTIMISE II pivotal trial of Kalios, an adjustable mitral ring, as well as the start of a pilot/pivotal study of its Artus implantable urinary sphincter for urinary incontinence.

The OPTIMISE II trial got underway in December and is slated to complete enrollment of about 62 patients in four European countries this quarter. The goal is to demonstrate Kalios safety and effectiveness as a treatment for post-operative residual valve insufficiency. Primary outcomes from the trial are after 12-month follow-up early next year, with commercialization possibly in about two years, Finance said.

Additionally, Affluent Medical announced 5.5 million (US$6.2 million) in financing from two government-backed loans: 2.2 million from the banks Socit Gnrale and BNP Paribas to mitigate COVID-19s economic impact; 1 million by Bpifrance to support cardiology R&D; and 2.3 million in grants from Bifrance for the MINERVA study.

The new funding brings Affluent Medicals total capital raised to about 38 million since 2012.

In conjunction with the financing, the company named Jean-Franois Le Bigot, CEO of Oncovita and chairman of Ginko Invest, and Benot Adelus, president of Fate, as board members. Rounding out the board appointments was Finance, who was elected as chairman.

We are very pleased to welcome Jean-Franois Le Bigot and Benot Adelus to our board of directors, Finance said. Their expertise along with the 15.8 million in refinancing should allow Affluent Medical to make rapid progress on its clinical programs and its commitment to bring new-generation, minimally invasive medical devices to the market for the treatment of large unmet medical needs.

Read this article:
Affluent Medical kicks off first-in-human trial of Epygon valve - BioWorld Online

Physiology

Local students named to U of I Dean’s List – Oskaloosa Herald

IOWA CITY More than 8,500 undergraduate students at the University of Iowa were named to the dean's list for the 2020 spring semester, including 47 students from Mahaska and Marion Counties.

The following students were named to the list:

Austin Adrian of Pella, Accounting; Chance Bodart of Oskaloosa, Journalism and Mass Communication; Payton Bumgardner of Pleasantville, History; Allison Clark of Leighton, History; Spencer De Jong of Oskaloosa, History; Alicia Edmundson of New Sharon, English and Creative Writing; Taylor Fleener of Oskaloosa, Anthropology; John Hammes of Oskaloosa, Economics; Kaila Hembrook of Knoxville, Communication Studies; Tessa Hutchings of Pleasantville, Art; Kaley Iddings of Pleasantville, Speech and Hearing Science; Anna Kain of Oskaloosa, Art; Emma Kelderman of Oskaloosa, Pre-Business; Joseph Kesteloot of Knoxville, Microbiology; Makayla Kruse of Pella, Human Physiology; Alice Lickteig of Pella, Elementary Education; Isaiah Martin of Pella, Actuarial Science; Emily Masek of Otley, Speech and Hearing Science; Blake McClung of Knoxville, Business Analytics and Information Systems; Jared McClung of Knoxville, Mechanical Engineering; Jackson McDonald of Knoxville, Communication Studies; Bailee Meyer of Pella, English Education; Carson Milledge of Oskaloosa, Computer Science; Aubrey Miller of Oskaloosa, Elementary Education; John Moore of Oskaloosa, Finance; Maria Moore of Hamilton, Geoscience; Camryn Norton of Knoxville, Environmental Engineering; Lucy Olson of Knoxville, Neuroscience; Emma Padellford of Pleasantville, Enterprise Leadership; Victoria Palmer of Oskaloosa, Health and Human Physiology; Emily Parker of Pleasantville, English; Aleona Pronina of Pella, Psychology; Jarod Robertson of Pella, Art; Cara Roquet of Fremont, Elementary Education; Joel Ruiter of Otley, Human Physiology; Jordyn Sanders of Bussey, Science Studies; Victoria Sheehey of Pleasantville, Art; Colton Spaur of Bussey, Sport and Recreation Management; Kelli Spaur of Bussey, English; Andelyn Sunderman of Pella, Communication Studies; Daniel Thompson of Pella, Music Education; Morgan Thorpe of Pleasantville, Speech and Hearing Science; Tianna Torrejon of Pleasantville, Journalism and Mass Communication; Colin Vasina of Pella, Management; Jessica Vogel of Pella, Ancient Civilization; College: Josephine Vroom of Pella, Management; and Jennifer Wieser of Pella, Management.

We are making critical coverage of the coronavirus available for free. Please consider subscribing so we can continue to bring you the latest news and information on this developing story.

Go here to see the original:
Local students named to U of I Dean's List - Oskaloosa Herald

Physiology

Prevalence of Diabetic Retinopathy and Its Associated Factors among Di | DMSO – Dove Medical Press

Melkamu Tilahun,1 Teshome Gobena,2 Diriba Dereje,2 Mengistu Welde,2 Getachew Yideg3

1Department of Biomedical Sciences (Medical Physiology), College of Medicine and Health Sciences, Debre Markos University, Debre Markos, Ethiopia; 2Department of Biomedical Sciences, College of Medicine and Health Sciences, Jimma University, Jimma, Ethiopia; 3Department of Biomedical Sciences (Medical Physiology), College of Medicine and Health Sciences, Debre Tabur University, Debre Tabur, Ethiopia

Correspondence: Melkamu TilahunDepartment of Biomedical Sciences (Medical Physiology), College of Medicine and Health Sciences, Debre Markos University, PO Box 269, Debre Markos, EthiopiaTel +251 93-355-5884Fax + 0587780673Email melkamutilahunalamir@gmail.com

Background: Diabetic retinopathy is a well-known sight-threatening microvascular complication of diabetes mellitus. Currently, 93 million people live with diabetic retinopathy worldwide. There are insufficient studies addressing the prevalence of diabetic retinopathy and risk factors in Ethiopia.Objective: To assess the prevalence of diabetic retinopathy and its associated factors among diabetic patients on follow-up at Debre Markos Referral Hospital, northwest Ethiopia, 2019.Methods: This institution- based cross-sectional study was conducted among 302 patients. They were selected through systematic sampling. Explanatory data were extracted from medical records and interviews. Blood pressure, weight, height, and visual acuity tests were assessed. Retinal examination was performed with a Topcon TRC-NW7SF fundus camera. Data were entered in EpiData 3.1 and exported in to SPSS 20 for analyses. Binary logistic regression with 95% CIs was used for analyses. Simple binary logistic regression followed by multiple binary logistic regression analysis was conducted to identify associated factors.Results: There were 302 patients in this study, of which 57 (18.9%) had diabetic retinopathy. Among the diabetic retinopathy patients, 75.4% had the preproliferative type. Four in ten (37.7%) of the patients had visual acuity problems. Poor glycemic control (AOR 4.58, 95% CI 1.86 11.31), > 10 years diabetes duration (AOR 3.91, 95% CI 1.86 8.23), body-mass index > 25 kg/m2 (AOR 3.74, 95% CI 1.83 7.66), and hypertension (AOR 3.39, 95% CI 1.64 7.02) were factors significantly associated with diabetic retinopathy.Conclusion: About a-fifth of diabetic patients had diabetic retinopathy. Diabetic retinopathy was significantly associated with glycemic control, hypertension, body-mass index, and duration of illness. Routine assessment and early control of those associated factors may be important in reducing both the prevalence and impact of diabetic retinopathy, as evidenced in the current study.

Keywords: diabetes mellitus, diabetic retinopathy, associated factor, Ethiopia

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Go here to read the rest:
Prevalence of Diabetic Retinopathy and Its Associated Factors among Di | DMSO - Dove Medical Press

Physiology

Empatica and BARDA Join Forces to Validate Wearable System That Detects COVID-19 Before Symptoms Appear – PRNewswire

The aim is to validate Empatica's algorithm in real-life settings, with the participation of healthcare workers who are exposed to a high viral load while treating hospitalized COVID-19 patients.They will wear the E4, Empatica's medical-grade research wearable wristband, for 30 days, and their physiological data will be reviewed against daily nasopharyngeal (NP) samples and a daily qRT-PCR swab, ensuring the highest ground truth.

Empatica CEO Matteo Lai, stated, "We are very proud to join forces with BARDA to help improve the health and safety of millions of Americans going back to work. This product introduces a new paradigm: empowering individuals and institutions with smart health monitoring, so that they will know early when they need to self-isolate and take care of themselves. Without BARDA's leadership and foresight over the past year, our early detection algorithm would not have reached this pivotal stage of clinical validation, which will accelerate our request for FDA's approval of Aura as a medical product for use by people at risk of contracting COVID-19."

BARDA Acting Director, Gary Disbrow, Ph.D., added, "We anticipate that access to real-time and actionable health information will empower people to seek medical advice and care sooner, or to adopt behavioral changes such as temporary self-isolation that can help reduce the spread of COVID-19 and similar infections."

Early detection can protect frontline workers, reduce spread, and improve the overall public health response as lockdowns ease globally. Recent estimates byCDC suggest that 35% of infections are asymptomatic, making contact tracing and containment of the virus a challenge. Meanwhile,the most infectious period could be 1 to 3 days before symptoms start, so even those patients who eventually display symptoms can still infect their family, colleagues and other people they interact with, before realizing they are ill. Digital biomarkers like Aura can help efficiently triage patients, enabling more effective care and prioritization of cases, and potentially saving lives.

Contact [emailprotected] for more info on Aura.

Empatica

Empatica Incis an MIT spinoff based in Boston, MA, and a pioneer in physiology-based biomarker development and continuous, unobtrusive patient monitoring driven by AI. Empatica's platform uses a combination of biosensors to detect features of human physiology that are distilled in AI-based algorithms and can remotely monitor autonomic activity, movement, sleep and cardiac activity. Empatica's E4 and Embrace2 smartwatches are CE-marked and have been sold to thousands of institutional partners for research purposes, in trials and studies examining Stress, Sleep, Epilepsy, Migraine, Depression, Addiction and other conditions.

HHS/ASPR/BARDA

HHS works to enhance and protect the health and well-being of all Americans, providing for effective health and human services and fostering advances in medicine, public health, and social services. The mission of ASPR is to save lives and protect Americans from 21st century health security threats. Within ASPR, BARDA invests in the innovation, advanced research and development, acquisition, and manufacturing of medical countermeasures vaccines, treatments, diagnostic tools, and non-pharmaceutical products needed to combat health security threats.

SOURCE Empatica

https://www.empatica.com/

Excerpt from:
Empatica and BARDA Join Forces to Validate Wearable System That Detects COVID-19 Before Symptoms Appear - PRNewswire

Biochemistry

Black people are underrepresented in medical research. She wants to change that. – News@Northeastern

For as long as Shellaina Gordon can remember, the word research for her has conjured images of white laboratory coats and tubes of solution. But inside those lab coats, she never saw anyone who looked like her.

And yet, growing up in a family of seven that has dealt with plenty of sickness, Gordon has always found herself drawn to the field of difficult-to-treat diseases, and specifically the study of the proteins involved in human disease, and how their expression, structure and function cause illness.

She decided early on that she wanted to pursue a career in science and medicine to help reduce the healthcare disparities that adversely affect underrepresented communities.

There is a lack of physician-scientists working at this level and especially those of color, says Gordon, a biochemistry student who is in her third year at Northeastern. My hopes are to counteract this reality by exploring disease proteomics at the molecular levelunderstanding the fundamental differences between different groups of people will be instrumental in developing useful, effective therapeutics.

An aspiring physician-scientist, Gordon says she intends to learn how the intricacies of medicine intersect with socioeconomic status and race in the development of treatments. Her research goals include learning about the onset and progression of disease in different ethnic groups. She also wants to teach and mentor undergraduate students, especially those who come from underserved backgrounds.

At some point in my career, I hope to become a tenured professor at a research-intensive university running my own lab, she says.

Gordons research career began in the lab of Teresita Padilla-Benavides, an assistant professor of biochemistry and molecular pharmacology at the University of Massachusetts Medical School. Under Padilla-Benavides tutelage, Gordon has published three scientific journal articles on projects she completed that explored the role of transition metalswhich include metals such as manganese, copper, and zincin the development of cells.

At Northeastern, Gordon is treasurer of the student diversity advisory council of the College of Science and of the womens club water polo team. She is also a member of the Black Engineering Student Society, where she says she has found community and interdisciplinary discussions of science.

I have been able to network and take advantage of opportunities in STEM [science, technology, engineering, and mathematics], she says.

Earlier this year, Gordon was rewarded with a Goldwater Scholarship to support her pursuit of a career in medicine and science.

Established by Congress to honor Sen. Barry Goldwater, the Goldwater Scholarship is a highly competitive, merit-based award given to college students who plan to pursue research careers in mathematics, engineering, and the natural sciences.

I am incredibly honored to be a part of such an elite, aspirational community, Gordon says. Although I aspire to be a physician-scientist, I anticipate my path to this career will not be linear. In this final year, I hope to further understand where I can make an impact on science and in the world and then act on it.

For media inquiries, please contact media@northeastern.edu.

View original post here:
Black people are underrepresented in medical research. She wants to change that. - News@Northeastern

Biochemistry

Biochemical Diagnostic Reagent Market | Covid-19 Impact | Demand, Cost Structures, Latest trends, and Forecasts to 2024 | Key Players: Roche, Siemens…

Biochemical Diagnostic Reagent Market with Covid-19 Impact Analysis: Forecast to Show Spurring Growth by 2020-2024 to its research database. The global Biochemical Diagnostic Reagent Market research report is an output of a brief assessment and an extensive analysis of practical data collected from the global Biochemical Diagnostic Reagent market. The data are collected on the basis of industrial drifts and demands related to the services & products. The meticulously collected data offers for the process of effortless strategic planning. It also helps in creating promising business alternatives.

Free Sample Report + All Related Graphs & Charts @ https://www.acquiremarketresearch.com/sample-request/362392/

A perfect demonstration of the recent expansions and innovative technological resolutions offer our customers the liberty to develop their decision-making skills. This ultimately helps to work with perfect business alternatives and apply elegant implementations. The global Biochemical Diagnostic Reagent Market report emphasizes the latest developments, growth, new opportunities, and dormant tricks. It provides an all-inclusive stance of the global Biochemical Diagnostic Reagent Market. Requirement proportion and innovation of modern technologies are some of the key factors covered in the global Biochemical Diagnostic Reagent Market report.

Our Free Complimentary Sample Report Accommodate a Brief Introduction of the research report, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology.

This helps to understand the overall market and to recognize the growth opportunities in the global Biochemical Diagnostic Reagent Market. The report also includes a detailed profile and information of all the major market players currently active in the global Biochemical Diagnostic Reagent Market. The companies covered in the report can be evaluated on the basis of their latest developments, financial and business overview, product portfolio, key trends in the market, long-term and short-term business strategies by the companies in order to stay competitive in the market.

Download Free PDF Report Brochure @ https://www.acquiremarketresearch.com/sample-request/362392/

Some of the Major Market Player Profile Included in This Report is:

Roche, Siemens Healthineers, Beckman Coulter, Randox, BioSino, Beijing Leadman Biochemistry, FosunPharma, Beijing Strong Biotechnologies, Dojindo Laboratories, Sysmex, KAINOS Laboratories, DAAN Gene

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into Liquid Double Reagent, Dry Powder Double Reagent .

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including Hospital, Clinic, Laboratory.

The greater part of the data gathered is presented in graphical form along with the related statistics. The global Biochemical Diagnostic Reagent Market report demonstrates the functioning of the main market players, suppliers, and dealers in detail. The report also highlights the restraints and drivers impacting the global Biochemical Diagnostic Reagent Market.

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

(*If you have any special requirements, please let us know and we will offer you the report as you want.)

The report analyzes various decisive constraints such as item price, production capability, profit & loss statistics, and transportation & delivery channels influencing the global Biochemical Diagnostic Reagent Market. It also covers the analysis of other important elements such as market demands, advancements, and product developments, various organizations, and processes impacting the global Biochemical Diagnostic Reagent Market. The global Biochemical Diagnostic Reagent Market research report emphasizes a variety of modifications done that improve the work process of the global Biochemical Diagnostic Reagent Market.

Grab Your Report at an Impressive Discount (Use Corporate email ID to Get Higher Priority) @ https://www.acquiremarketresearch.com/discount-request/362392/

A methodically structured Biochemical Diagnostic Reagent Market research report is based on the primary and secondary resource. It portrays the data collected in a more communicative and expressive way allowing the customer to develop a well-structured plan to develop and expand their businesses in the estimated duration.

Promising Regions & Countries Mentioned in The Biochemical Diagnostic Reagent Market Report:

North America: United States, Canada, and Mexico.South & Central America: Argentina, Chile, and Brazil.Middle East & Africa: Saudi Arabia, UAE, Turkey, Egypt and South Africa.Europe: UK, France, Italy, Germany, Spain, and Russia.Asia-Pacific: India, China, Japan, South Korea, Indonesia, Singapore, and Australia.

Buy Full Copy Global Biochemical Diagnostic Reagent Report 2020-2024 @ https://www.acquiremarketresearch.com/buy-now/362392/?price=su

COVID-19- Current Scenario & Potential Impact

Various communities and companies are doing their best to function and perform, and eventually cope with the challenges raised by COVID-19 pandemic. The COVID-19 pandemic had a negative impact on the market size for the year 2020, with small and medium scale companies struggling to sustain their businesses in the near-term future. Industry leaders are now focusing to create new business practices to deal with crisis situations like COVID-19 pandemic.

The report presents a strategic analysis of the Biochemical Diagnostic Reagent market through key drivers, challenges, opportunities, and growth contributors. Further, the market attractiveness index is provided based on five forces analysis.

The Biochemical Diagnostic Reagent market delivers value to customers through reliable market size for 2019 on the basis of demand and price analysis. The report presents near term and long term forecast of the addressable Biochemical Diagnostic Reagent market size to 2024.

(We customize your report according to your research need. Ask our sales team for report customization. [emailprotected])

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About us:

Acquire Market Research is a market research-based company empowering companies with data-driven insights. We provide Market Research Reports with accurate and well-informed data, Real-Time with Real Application. A good research methodology proves to be powerful and simplified information that applied right from day-to-day lives to complex decisions helps us navigate through with vision, purpose and well-armed strategies. At Acquire Market Research, we constantly strive for innovation in the techniques and the quality of analysis that goes into our reports.

Contact Us:

Sally Mach555 Madison Avenue,5th Floor, Manhattan,New York, 10022 USAPhone No.: +1 (800) 663-5579Email ID: [emailprotected]

Go here to see the original:
Biochemical Diagnostic Reagent Market | Covid-19 Impact | Demand, Cost Structures, Latest trends, and Forecasts to 2024 | Key Players: Roche, Siemens...

Biochemistry

Postdoc position in time-resolved crystallography (1.0 FTE) (220213) – Nature.com

Job descriptionWe are looking for a postdoctoral fellow with backgrounds in crystallography or related fields who are motivated to work in an interdisciplinary research environment studying the dynamics of membrane transporters using the combination of photopharmacology and time-resolved crystallography. This research project is financially supported by the Dutch Science Foundation.In this project, the membrane protein dynamics during a ligand binding will be assessed both on millisecond (using synchrotron radiation) and femtosecond scale (using XFELs). Biochemistry and crystallisation protocols are in place. The nature of the project requires considerable travelling for data collection at synchrotron facilities.The postdoctoral fellow will become a member of the research group led by Dr. Albert Guskov, which is embedded in the GBB research Institute. The fellow will have access to cutting-edge structural biology facilities, both in-house (crystallisation and optimisation robots, imager, etc.) as well as access to top research facilities such as ESRF, Petra III, Eu-XFEL and PAL for measurements.Postdoctoral fellows can receive training and advanced courses or workshops on generic research, transferable skills and teaching. Postdoctoral fellows at the Faculty of Science and Engineering also benefit from a Postdoc community to meet peers.As a postdoctoral fellow, you are committed to conduct independent and original scientific research, to report on this research in international publications and presentations. Postdoctoral fellows are expected to contribute about 10% of their overall workload to teaching.QualificationsThe candidates should have the following qualifications: a PhD degree with specialisation in structural biology, biochemistry, chemistry, biophysics, or related field is required excellent communication and writing skills in English ability to work independently and in a team proven experience in membrane protein production, purification and crystallisation experience in macromolecular crystallography experience in serial crystallography (data collection, data processing) is an advantage.OrganisationFounded in 1614, the University of Groningen enjoys an international reputation as a dynamic and innovative centre of higher education offering high-quality teaching and research. Flexible study programmes and academic career opportunities in a wide variety of disciplines encourage the 32,000 students and researchers alike to develop their own individual talents. As one of the best research universities in Europe, the University of Groningen has joined forces with other top universities and networks worldwide to become a truly global centre of knowledge.The Groningen Biomolecular Sciences and Biotechnology Institute (GBB), one of the larger institutes of the Faculty of Science and Engineering (FSE), provides an excellent environment for top-notch research in the field of biomolecular sciences. Twelve vibrant research groups with strong roots in biochemistry, biophysical chemistry, cell biology, computational biology, genetics, microbiology, molecular biology, and systems biology are organised in two focal areas: Molecular Mechanisms of Biological Processes and Physiology and Systems Biology.Conditions of employmentWe offer you in accordance with the Collective Labour Agreement for Dutch Universities: a salary based on qualifications and experience, starting at 3,353 gross per month (salary scale 10), based on a fulltime position (1.0 FTE) a holiday allowance of 8% an 8.3% year-end bonus.The position offered is for 3 years. Each successful candidate will first be offered a temporary position of one year with the option of renewal for another 2 years. Prolongation of the contract is contingent on sufficient progress in the first year.The starting date is flexible.ApplicationYou may apply for this position until 15 July (23:59 h) / before 16 July 2020 (00:00h) 2020 Dutch local time by means of the online application form (click on Apply below on the advertisement on the university website).Applications for the position should include (as a single PDF file): cover letter with background and motivation to apply for this position curriculum vitae, including details of your PhD degree and the publication list contact details of 2-3 academic references, including your PhD supervisor.Interviews are scheduled to take place in July & August 2020. The envisaged starting date is 1 September 2020, but is negotiable.We are an equal opportunity employer and value diversity at our University. We are committed to building a diverse faculty so you are encouraged to apply. Our selection procedure follows the guidelines of the Recruitment code (NVP), http://nvp-plaza.nl/download/?id=7714 and European Commissions European Code of Conduct for recruitment of researchers, https://euraxess.ec.europa.eu/jobs/charter/codeUnsolicited marketing is not appreciated.InformationFor information you can contact:Dr. Albert Guskov, a.guskov@rug.nlPlease do not use the e-mail address(es) above for applications.Additional informationGroningen Biomolecular Science and Biotechnology InstituteCurrent research group and output of Dr. Albert Guskov 1/2Current research group and output of Dr. Albert Guskov 2/2

Read more:
Postdoc position in time-resolved crystallography (1.0 FTE) (220213) - Nature.com

Biochemistry

SINTX Technologies Announces Publication of Study to Reduce the Spread and Transfer of Coronavirus – Business Wire

SALT LAKE CITY--(BUSINESS WIRE)--SINTX Technologies, Inc. (NASDAQ: SINT) (SINTX or the Company), an original equipment manufacturer (OEM) ceramics company focused on silicon nitride and its applications, today announced positive testing results demonstrating the anti-viral properties of its silicon nitride which may be useful in the reduction of the spread of COVID-19. The study results demonstrated that SINTXs unique grade of silicon nitride inactivates the SARS-CoV-2 virus within a minute after exposure, and has the potential to decrease the risk of viral disease spread on surfaces.

Studies have shown that coronavirus spreads between humans when an infected person coughs or sneezes. Also, the virus can remain active on a variety of commonly touched surfaces for hours to days. SINTX believes that by incorporating its unique composition of silicon nitride into products such as face masks, and personal protective equipment, it is possible to manufacture surfaces that inactivate viral particles, thereby limiting the spread of the disease. SINTX envisions incorporating its silicon nitride into high-contact surfaces such as medical equipment, screens, countertops, and doorknobs in locations where viral persistence is a concern, such as homes, casinos, and cruise ships.

The study builds upon years of research toward understanding the basic biochemistry of silicon nitride, said Dr. Sonny Bal, President, and CEO of SINTX. The antiviral attributes of silicon nitride are consistent with the known antibacterial behavior of silicon nitride. The results with coronavirus inactivation are likewise consistent with an earlier study that showed similar inactivation of other viruses, including Influenza A and Enterovirus, both of which cause human disease.

The study and testing results show promise toward developing a new category of face masks for healthcare professionals and general consumers, said Bruce Lorange, Founder, and CEO, O2TODAY. Face masks used by healthcare workers today can capture virus particles, but the virus can remain viable in the mask, even as long 7 days after use. Inclusion of silicon nitride technology into the mask may enhance personal safety while reducing the risk of disease spread.

This antiviral discovery opens many new opportunities for SINTX. In composites, coatings, and mixtures, silicon nitride has maintained its antibacterial and osteogenic properties, even at small fractions. We believe that incorporating our material into a variety of commonly-touched surfaces will discourage viral spread, and contribute to global health by reducing the risk of disease, Dr. Bal added.

The present study was done independently, with SINTX supplying its silicon nitride for the testing. The complete data and study can be downloaded at bioRxiv. Additional tests are underway at several U.S. research centers to further understand the isolation and optimization of the antiviral properties of silicon nitride; those results will be shared as they become available.

About SINTX Technologies, Inc.

SINTX Technologies is an OEM ceramics company that develops and commercializes silicon nitride for medical and non-medical applications. The core strength of SINTX Technologies is the manufacturing, research, and development of silicon nitride ceramics for external partners. The Company manufactures silicon nitride material and components in its FDA registered and ISO 13485 certified facility. For more information on SINTX Technologies or its silicon nitride material platform, please visit http://www.sintx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended (PSLRA) that are subject to several risks and uncertainties. Risks and uncertainties that may cause such differences to include, among other things, that SINTX has not developed any PPE products which incorporate the use of silicon nitride, incorporation of silicon nitride into PPE may not be safe or effective; the uncertainties inherent in research and development, including the cost and time required to advance our products to regulatory submission; market acceptance of our products once cleared and commercialized; our ability to raise additional funding and other competitive developments. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect managements current estimates, projections, expectations, and beliefs. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in SINTXs Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 26, 2020, and in SINTXs other filings with the SEC. SINTX disclaims any obligation to update any forward-looking statements. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report.

Read this article:
SINTX Technologies Announces Publication of Study to Reduce the Spread and Transfer of Coronavirus - Business Wire